Lab Sciences
Top stories summarized by our editors
5/9/2018

Researchers from the Children's National Health System in Maryland have been observing 36 infants who were exposed to the Zika virus during pregnancy but did not manifest any abnormalities in prenatal or postnatal neuroimaging. At 6 months, the babies' neuromotor skills were similar to those of 68 infants unexposed to Zika, according to a study presented at the Pediatric Academic Societies annual meeting.

5/9/2018

Democratic Republic of Congo health officials said on Tuesday that a new outbreak of Ebola has been confirmed with 21 patients manifesting symptoms of hemorrhagic fever and 17 dying in the affected area, a village in the northwest of the country.

Full Story:
Reuters
5/8/2018

Laboratories should specify the type of assay -- whether HPV DNA tests or HPV mRNA tests -- used in HPV screening of patients who have had one previous high-risk HPV-positive result, as well as those who have had at least two hrHPV-positive results, because it could affect patient follow-up, researchers found. The authors said they hope their findings "will start conversations between gynecologists and pathologists to be sure the HPV DNA test is used for primary screening to identify those at potential long-term risk."

More Summaries:
HPV
5/8/2018

A group of international researchers used mouse models to study the role of the Y chromosome gene UTY in protecting against the development of acute myeloid leukemia. The findings were reported online in the journal Nature Genetics.

More Summaries:
Nature Genetics
5/8/2018

The Clarity Clostridium difficile toxins A/B assay by Singulex outperformed other currently used diagnostic tests by rapidly detecting toxins at 100 times lower concentrations, a study found. Singulex expects FDA registration for the test by the end of the year.

More Summaries:
Singulex, FDA
5/8/2018

A study in the journal PLOS Pathogens estimated that 84% of cases of dengue fever are the result of transmission from asymptomatic individuals. Researchers from the University of Notre Dame employed mathematical modeling based on demographics and disease characteristics and also found that 1% of transmissions are attributable to people whose infections have been clinically detected.

5/8/2018

Research seeking to determine why some patients with relapsed/refractory chronic lymphocytic leukemia do not respond to chimeric antigen receptor T-cell therapy has yielded data that may give drug developers and scientists a clue, according to findings published in the journal Nature Medicine. "Our biomarker, which is defined as CD27-positive, CD45RO-negative CD8+ T cells in pre-manufactured T cells, may help in patient selection," said senior study author Joseph Melenhorst.

More Summaries:
Nature Medicine
5/8/2018

A filing has been submitted by British biotech firm Autolus for an initial public offering in the US that could be worth $100 million. The proceeds from the IPO will advance research to make stem cell therapies safer by developing safety switches for the company's treatments.

Full Story:
Reuters, Endpoints News
5/8/2018

Patents for Gilead Sciences' hepatitis C drug sofosbuvir and HIV medication Truvada were rejected by Brazil and Europe, respectively, after patent challenges by the nonprofit Initiative for Medicines, Access & Knowledge and its partners. Two challenges brought by the nonprofit against Gilead for sofosbuvir in the US were blocked by the US Patent Trial and Appeal Board.

Full Story:
PharmaBiz (India)
More Summaries:
Gilead Sciences, Brazil, Europe, Truvada
5/7/2018

A study in the journal Cell describes how NIH researchers studied the cellular mechanisms that aid in the hibernation of the 13-lined ground squirrel. "By understanding the biology of cold adaptation in hibernation, we may be able to improve and broaden the applications of induced hypothermia in the future, and perhaps prolong the viability of organs prior to transplantation," said study co-author Wei Li of the National Eye Institute's Retinal Neurophysiology Section.

More Summaries:
Wei Li, National Eye Institute, NIH